1/9
08:02 am
kalv
KalVista Pharmaceuticals (NASDAQ:KALV) had its price target raised by analysts at HC Wainwright from $27.00 to $37.00. They now have a "buy" rating on the stock.
Medium
Report
KalVista Pharmaceuticals (NASDAQ:KALV) had its price target raised by analysts at HC Wainwright from $27.00 to $37.00. They now have a "buy" rating on the stock.
1/8
04:27 pm
kalv
KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results [Yahoo! Finance]
Medium
Report
KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results [Yahoo! Finance]
1/8
04:05 pm
kalv
KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results
Medium
Report
KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results
1/6
08:00 am
kalv
KalVista Pharmaceuticals (NASDAQ:KALV) had its price target raised by analysts at Needham & Company LLC from $28.00 to $32.00. They now have a "buy" rating on the stock.
Low
Report
KalVista Pharmaceuticals (NASDAQ:KALV) had its price target raised by analysts at Needham & Company LLC from $28.00 to $32.00. They now have a "buy" rating on the stock.
12/22
06:00 am
kalv
KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema
Low
Report
KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema
12/4
08:05 am
kalv
KalVista Pharmaceuticals (NASDAQ:KALV) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.
High
Report
KalVista Pharmaceuticals (NASDAQ:KALV) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.
12/3
03:13 pm
kalv
KalVista Pharmaceuticals (NASDAQ:KALV) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Low
Report
KalVista Pharmaceuticals (NASDAQ:KALV) had its "buy" rating reaffirmed by analysts at Cowen Inc.
11/18
06:38 am
kalv
Citizens Touts KalVista Pharmaceuticals, Inc. (KALV) Growth Trajectory on EKTERLY Prospects [Yahoo! Finance]
Low
Report
Citizens Touts KalVista Pharmaceuticals, Inc. (KALV) Growth Trajectory on EKTERLY Prospects [Yahoo! Finance]
11/11
04:26 pm
kalv
KalVista Pharmaceuticals Inc (KALV) Q3 2026 Earnings Call Highlights: Strong EKTERLY Launch and ... [Yahoo! Finance]
High
Report
KalVista Pharmaceuticals Inc (KALV) Q3 2026 Earnings Call Highlights: Strong EKTERLY Launch and ... [Yahoo! Finance]
11/11
01:42 pm
kalv
KalVista Pharmaceuticals, Inc. (KALV) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
KalVista Pharmaceuticals, Inc. (KALV) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/11
09:06 am
kalv
KalVista Pharmaceuticals (NASDAQ:KALV) had its price target lowered by analysts at Citizens Jmp from $29.00 to $28.00. They now have a "market outperform" rating on the stock.
Low
Report
KalVista Pharmaceuticals (NASDAQ:KALV) had its price target lowered by analysts at Citizens Jmp from $29.00 to $28.00. They now have a "market outperform" rating on the stock.
11/11
07:03 am
kalv
KalVista Pharmaceuticals (NASDAQ:KALV) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
KalVista Pharmaceuticals (NASDAQ:KALV) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
11/10
07:41 pm
kalv
KalVista Pharmaceuticals, Inc. (KALV) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
Medium
Report
KalVista Pharmaceuticals, Inc. (KALV) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
11/10
05:17 pm
kalv
KalVista Pharmaceuticals GAAP EPS of -$0.92, revenue of $13.69M [Seeking Alpha]
Low
Report
KalVista Pharmaceuticals GAAP EPS of -$0.92, revenue of $13.69M [Seeking Alpha]
11/10
05:00 pm
kalv
KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results [Yahoo! Finance]
Low
Report
KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results [Yahoo! Finance]
11/10
04:30 pm
kalv
KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results
Medium
Report
KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results
11/6
08:01 am
kalv
KalVista Pharmaceuticals Presents New Data Highlighting Patient Satisfaction with EKTERLY® (sebetralstat) and its Potential in Children Ages 2-11 at the ACAAI 2025 Annual Scientific Meeting
Medium
Report
KalVista Pharmaceuticals Presents New Data Highlighting Patient Satisfaction with EKTERLY® (sebetralstat) and its Potential in Children Ages 2-11 at the ACAAI 2025 Annual Scientific Meeting
11/5
07:00 am
kalv
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
Low
Report
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
11/3
07:00 am
kalv
KalVista Pharmaceuticals to Host Third Quarter Financial Results Conference Call and Webcast on November 11, 2025
Medium
Report
KalVista Pharmaceuticals to Host Third Quarter Financial Results Conference Call and Webcast on November 11, 2025
10/30
07:00 am
kalv
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting
Low
Report
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting